Ireland
⚡ Actively retaliating against US tariffs
Ireland punches wildly above its weight in US trade statistics. With a population of just 5 million, it runs a $76.3 billion trade deficit with the US — larger than Japan's. The explanation lies in Ireland's status as the European headquarters for American pharmaceutical and tech giants. Pfizer, Johnson & Johnson, Abbvie, and dozens of other pharma companies manufacture drugs in Ireland and export them back to the US.
Current Tariff
📊20%
Was 2.2%
US Imports
📥$91.5B
2024 total
US Exports
📤$15.2B
2024 total
Trade Balance
⚖️$-76.3B
US deficit
Trade Flow (2024)
Tariff Rate Change
📈 5-Year Import Trend
📋 Trade Relationship Analysis
Ireland punches wildly above its weight in US trade statistics. With a population of just 5 million, it runs a $76.3 billion trade deficit with the US — larger than Japan's. The explanation lies in Ireland's status as the European headquarters for American pharmaceutical and tech giants. Pfizer, Johnson & Johnson, Abbvie, and dozens of other pharma companies manufacture drugs in Ireland and export them back to the US.
This creates a statistical illusion: much of the 'Irish' exports to America are actually American companies' products manufactured in Ireland for tax advantages, then shipped home. Ireland's 12.5% corporate tax rate (now 15% under OECD minimum tax) has made it the pharma capital of Europe. The 20% EU-wide tariff essentially taxes American companies' own products.
Medical devices are another major category — Medtronic, Boston Scientific, and Stryker all have major Irish operations. Nine of the world's top ten medtech companies manufacture in Ireland. Tariffs on these goods directly increase US healthcare costs.
As an EU member, Ireland's trade policy is set in Brussels, and EU retaliation applies uniformly. However, the unique nature of Ireland's pharma-heavy trade — where tariffs mostly hurt American companies rather than Irish ones — may create pressure for sector-specific exemptions. The Irish government has been lobbying EU partners and Washington for pharmaceutical carve-outs.
Tariff Impact
Pre-2025
2.2%
Current
20%
Increase
+17.8%
🏷️ Top Imported Products
| Product | Tariff Rate | Import Value | Price Impact |
|---|---|---|---|
| Pharmaceuticals (Pfizer, Abbvie) | 20% | $48.6B | +10-20% on branded drugs |
| Medical Devices (Medtronic, Stryker) | 20% | $14.2B | +$10K-100K per device |
| Organic Chemicals | 20% | $12.8B | +12-18% input costs |
| Software & Digital Services | 20% | $6.4B | +5-10% licensing costs |
| Dairy Products (Kerrygold) | 20% | $1.2B | +$1-3 per product |
📅 Tariff Timeline
🎯 Retaliation — US Products Targeted
| US Product Targeted | US Exports at Risk | Estimated Loss |
|---|---|---|
| Part of EU-wide retaliation package | N/A | N/A |
| US Tech Services (as EU trade partner) | $15.2B | $2.5B |
💡 Did You Know?
- •Ireland's trade deficit with the US is larger than Japan's — despite having 1/25th the population
- •Nine of the world's top 10 pharmaceutical companies have manufacturing operations in Ireland
- •Kerrygold butter, Ireland's most famous consumer export, saw US sales exceed $1B in 2024
- •Over 900 US companies operate in Ireland, employing 200,000 people — 10% of Ireland's entire workforce